# US 2019/0292237 A1 · Compositions comprising a p75 tumor necrosis factor receptor/ig fusion protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0292237 A1
- Document ID: US20190292237A1
- Status: Published application
- Kind: A1
- Application number: 16/396,352
- Filed: 2019-04-26
- Published: 2019-09-26
- Earliest claimed: 2002-02-27
- Assignees: Immunex Corporation
- Applicants: Immunex Corporation
- Inventors: Wayne Richard Gombotz; Richard L. Remmele, JR.
- Web page: https://patentgrep.com/patent/US20190292237A1

## CPC

- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 16/18: against material from animals or humans
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- Y10S 435/81: Packaged device or kit
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention relates to an aqueous pharmaceutical composition suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin, methods of manufacture, methods of administration and kits containing same.

## Claims

### Claim at position 1

-30. (canceled)

### Claim 31

A method of treating rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis in a subject in need thereof, the method comprising administering to the subject a weekly single subcutaneous dose of about 10-80 mg of etanercept,
wherein the etanercept is administered in a pharmaceutical composition comprising about 50 mg/ml etanercept, an excipient, and a buffer; wherein the excipient is lysine and the buffer is sodium citrate; wherein the pharmaceutical composition does not comprise arginine; and
wherein the composition has not been lyophilized.

### Claim 32 (depends on 31)

The method of claim 31, wherein the sodium citrate of the pharmaceutical composition is present at a concentration of about 10 mM to about 200 mM.

### Claim 33 (depends on 31)

The method of claim 31, wherein the pharmaceutical composition further comprises sodium chloride at a concentration of about 10 mM to about 200 mM.

### Claim 34 (depends on 31)

The method of claim 31, wherein the pharmaceutical composition further comprises sucrose at a concentration of about 10 mM to about 200 mM.

### Claim 35 (depends on 31)

The method of claim 31, wherein the pharmaceutical composition comprises 50 mg/ml etanercept, lysine at a concentration of about 0.1-2 wt %, sodium citrate at a concentration of about 10 mM to about 200 mM, sodium chloride at a concentration of about 10 mM to about 200 mM, and sucrose at a concentration of about 10 mM to about 200 mM.

### Claim 36 (depends on 31)

The method of claim 31, wherein the pharmaceutical composition has been stored for three months at 2-8° C. in a prefilled syringe or injector pen.

### Claim 37 (depends on 36)

The method of claim 36, wherein the pharmaceutical composition does not lose more than 5% of its TNF binding activity at three months stored at 2-8° C. relative to the binding activity of the composition at the beginning of storage.

### Claim 38 (depends on 31)

The method of claim 31, wherein the subject has rheumatoid arthritis.

### Claim 39 (depends on 31)

The method of claim 31, wherein the subject has psoriatic arthritis.

### Claim 40 (depends on 31)

The method of claim 31, wherein the subject has ankylosing spondylitis.

### Claim 41

A method comprising
(a) forming an aqueous pharmaceutical composition comprising etanercept, an excipient and a buffer, and
(b) storing the aqueous pharmaceutical composition as a liquid for three months at 2-8° C., wherein the excipient is lysine, the buffer is sodium citrate, and
wherein the aqueous pharmaceutical composition does not comprise arginine.

### Claim 42 (depends on 41)

The method of claim 41, wherein the sodium citrate of the aqueous pharmaceutical composition of step (a) is present at a concentration of about 10 mM to about 200 mM.

### Claim 43 (depends on 41)

The method of claim 41, wherein the aqueous pharmaceutical composition of step (a) comprises from about 10 mg/mL to about 100 mg/mL etanercept.

### Claim 44 (depends on 43)

The method of claim 43, wherein the aqueous pharmaceutical composition of step (a) comprises about 50 mg/mL etanercept.

### Claim 45 (depends on 41)

The method of claim 41, wherein the aqueous pharmaceutical composition of step (a) further comprises sodium chloride at a concentration of about 10 mM to about 200 mM.

### Claim 46 (depends on 41)

The method of claim 41, wherein the aqueous pharmaceutical composition of step (a) further comprises sucrose at a concentration of about 10 mM to about 200 mM.

### Claim 47 (depends on 41)

The method of claim 41, wherein step (a) comprises forming an aqueous pharmaceutical composition comprising 50 mg/ml etanercept, lysine at a concentration of 0.1-2 wt %, sodium citrate at a concentration of about 10 mM to about 200 mM, sodium chloride at a concentration of about 10 mM to about 200 mM, and sucrose at a concentration of about 10 mM to about 200 mM.

### Claim 48 (depends on 41)

The method of claim 41, wherein the aqueous pharmaceutical composition of step (b) does not lose more than 5% of its TNF binding activity at three months stored at 2-8° C. relative to the binding activity of the composition at the beginning of storage.

### Claim 49

A method comprising
(a) forming an aqueous pharmaceutical composition comprising etanercept, an excipient and a buffer,
(b) freezing the aqueous pharmaceutical composition of step (a), and
(c) thawing the composition of step (b),
wherein the excipient is lysine, the buffer is sodium citrate, and wherein the aqueous pharmaceutical composition does not comprise arginine.

### Claim 50 (depends on 49)

The method of claim 49, wherein step (b) comprises freezing the composition at a temperature of −20° C. or less for a period of three months or more.

### Claim 51 (depends on 49)

The method of claim 49, wherein the sodium citrate of the aqueous pharmaceutical composition of step (a) is present at a concentration of about 10 mM to about 200 mM.

### Claim 52 (depends on 49)

The method of claim 49, wherein the aqueous pharmaceutical composition of step (a) comprises from about 10 mg/mL to about 100 mg/mL etanercept.

### Claim 53 (depends on 52)

The method of claim 52, wherein the aqueous pharmaceutical composition of step (a) comprises about 50 mg/mL etanercept.

### Claim 54 (depends on 49)

The method of claim 49, wherein the aqueous pharmaceutical composition of step (a) further comprises sodium chloride at a concentration of about 10 mM to about 200 mM.

### Claim 55 (depends on 49)

The method of claim 49, wherein the aqueous pharmaceutical composition of step (a) further comprises sucrose at a concentration of about 10 mM to about 200 mM.

### Claim 56 (depends on 49)

The method of claim 49, wherein step (a) comprises forming an aqueous pharmaceutical composition comprising 50 mg/ml etanercept, lysine at a concentration of about 0.1-2 wt %, sodium citrate at a concentration of about 10 mM to about 200 mM, sodium chloride at a concentration of about 10 mM to about 200 mM, and sucrose at a concentration of about 10 mM to about 200 mM.

### Claim 57 (depends on 49)

The method of claim 49, wherein the thawed composition of step (c) does not lose more than 5% of its TNF binding activity relative to the TNF binding activity of the aqueous pharmaceutical composition of step (a).

### Claim 58 (depends on 49)

The method of claim 49, further comprising (d) storing the thawed composition of step (c) for three months at 2-8° C.

### Claim 59 (depends on 49)

The method of claim 49, wherein the composition of step (d) does not lose more than 5% of its TNF binding activity relative to the TNF binding activity of the thawed composition of step (c).

### Claim 60 (depends on 49)

The method of claim 49, further comprising loading the thawed composition of step (c) into a syringe or injector pen, wherein etanercept is present at a concentration of 50 mg/ml.
